Pharmacovigilance (PV) is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem.
In 1968, during the 16th World Health Assembly, the 16.36 resolution led to the formation of the WHO Programme for International Drug Monitoring (PIDM).
The WHO Programme for International Drug Monitoring was set up in 1968 following the thalidomide tragedy and now plays an important role in global medicines safety monitoring. The WHO Programme for International Drug Monitoring is a group of more than 160 countries that share the vision of safer and more effective use of medicines. They work nationally and collaborate internationally to monitor and identify the harm caused by medicines, to reduce the risks to patients and to establish worldwide pharmacovigilance standards and systems.
The aim of this Newsletter is to disseminate information on the safety and efficacy of pharmaceutical products, based on information received from our network of "drug information officers" and other sources such as specialized bulletins and journals. The information is produced in the form of résumés in English
Congratulations to Malawi and Bosnia and Herzegovina! Members 135th and 136th of the WHO Programme for International Drug Monitoring. The WHO PIDM has now a total of 165 Members (136 Full Members and 29 Associate)